Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity (2021 - 2025)

Prime Medicine filings provide 5 years of Liabilities and Shareholders Equity readings, the most recent being $342.7 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 15.2% to $342.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 11.12% increase, with the full-year FY2025 number at $342.7 million, up 15.2% from a year prior.
  • Liabilities and Shareholders Equity hit $342.7 million in Q4 2025 for Prime Medicine, down from $385.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $385.0 million in Q3 2025 to a low of $193.9 million in Q4 2023.
  • Median Liabilities and Shareholders Equity over the past 5 years was $301.9 million (2021), compared with a mean of $296.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 46.2% in 2023 and later soared 53.47% in 2024.
  • Prime Medicine's Liabilities and Shareholders Equity stood at $301.9 million in 2021, then increased by 19.37% to $360.3 million in 2022, then tumbled by 46.2% to $193.9 million in 2023, then skyrocketed by 53.47% to $297.5 million in 2024, then rose by 15.2% to $342.7 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $342.7 million (Q4 2025), $385.0 million (Q3 2025), and $279.0 million (Q2 2025) per Business Quant data.